药物制剂

Search documents
因违法违规行为,金城医药董事长拟被罚150万元、禁入市场4年
Qi Lu Wan Bao· 2025-10-10 04:32
金城医药(300233.SZ)10月9日公告称,9月30日,公司收到实际控制人、董事长赵叶青的通知,因涉嫌操纵证券市场违法违规行为,其收到证监会重新下 发的《行政处罚事先告知书》(处罚字﹝2025﹞69号)。 内容显示,赵叶青、王震、刘峰涉嫌违反2005年《证券法》第七十七条第一款第一项、第三项的规定,构成2005年《证券法》第二百零三条所述操纵证券市 场的违法行为。对此,《告知书》拟决定如下: 一、依据2005年《证券法》第二百零三条的规定,对赵叶青、王震、刘峰处以300万元罚款,其中赵叶青承担150万元,王震承担120万元,刘峰承担30万 元。 二、依据2005年《证券法》第二百三十三条和《证券市场禁入规定》(证监会令第115号)第三条第一项、第七项和第五条的规定,对赵叶青采取4年市场禁 入措施;对王震采取3年市场禁入措施。自我会宣布决定之日起,在禁入期间内,除不得继续在原机构从事证券业务或者担任原上市公司、非上市公众公司 董事、监事、高级管理人员职务外,也不得在其他任何机构中从事证券业务或者担任其他上市公司、非上市公众公司董事、监事、高级管理人员职务。 金城医药表示,该《行政处罚事先告知书》所涉主体为赵 ...
商河县主导产业加速构建集群生态
Qi Lu Wan Bao· 2025-09-05 11:07
Core Insights - Shandong Shanghe County focuses on industrial chain extension, supplementation, and strengthening, actively attracting and nurturing "chain leader" enterprises while promoting the integration of small and medium-sized enterprises into the industrial chain [1] Industry Summaries Biopharmaceutical and Chemical Industry - The biopharmaceutical and chemical industry in Shanghe County has seen significant growth, with 47 large-scale enterprises gathered, forming a collaborative development pattern centered on key pharmaceutical intermediates, high-end raw materials, and drug formulations, aiming for a target of 10 billion [1] Equipment Manufacturing Industry - The equipment manufacturing industry has achieved multiple breakthroughs, with 42 large-scale enterprises introduced, including Guangri Co., Ltd. and the Jinan Digital Industry Park, leading to the development of industries such as laser manufacturing and elevator manufacturing from inception to growth [1] Nutritional Food Industry - The nutritional food industry is taking shape, led by major enterprises like Sibote Biotechnology and Jinsah River Noodle Industry, establishing the Qilu Health Food Industrial Park and enhancing cold chain storage logistics, thereby accelerating the transformation of agricultural product resource advantages into industrial development advantages [1]
链”上发力、提质向新,筑起工业强市“北翼支点
Qi Lu Wan Bao Wang· 2025-09-03 07:06
Core Viewpoint - The news highlights the strategic development of Jinan's industrial sector, particularly focusing on the "Industrial Strong City" initiative and the role of Shanghe County in enhancing industrial clusters and promoting a "chain-based" development model [1][3]. Group 1: Industrial Strategy and Development - Jinan's "Industrial Strong City" strategy aims for a significant upgrade in industrial capabilities by 2025, transitioning from "cluster development" to "chain-based breakthroughs" [1]. - Shanghe County is aligning its industrial development with Jinan's strategic goals, focusing on building a "chain-based" ecosystem that includes leading enterprises and small to medium-sized businesses [2][3]. Group 2: Key Industries and Clusters - The biopharmaceutical and chemical industries in Shanghe are developing a collaborative ecosystem, focusing on key pharmaceutical intermediates and high-end raw materials [2]. - Shanghe is establishing itself as a center for pharmaceuticals and high-end fine chemicals, contributing to Jinan's overall industrial strategy [3]. Group 3: Infrastructure and Service Innovations - Shanghe has introduced an innovative "park within a park" model to facilitate industrial clustering, providing specialized facilities tailored to different industry needs [4]. - The economic development zone in Shanghe is enhancing its infrastructure, including expanding steam supply capacity and wastewater treatment capabilities [4][6]. Group 4: New Production Capacity and Technological Advancements - Companies in Shanghe are focusing on digital transformation and smart manufacturing, with examples like Guangdian Elevator aiming to establish a digital factory [8]. - The region has nurtured specialized small and medium enterprises, contributing to the overall goal of transitioning from traditional manufacturing to intelligent manufacturing [9]. Group 5: Future Outlook and Goals - The year 2025 is pivotal for Jinan's industrial strategy, coinciding with the conclusion of the "Made in China 2025" initiative and the launch of new industrialization plans [9]. - Shanghe is committed to high-quality industrial development, aiming to contribute significantly to Jinan's industrial strength through innovation and strategic growth [9].
聚焦延链补链强链,商河县主导产业加速构建集群生态
Qi Lu Wan Bao Wang· 2025-09-02 07:53
Core Insights - The event focused on the "Industrial Strong City Development Strategy" in Jinan, highlighting the efforts of Shanghe County in enhancing its industrial chain and attracting key enterprises [1] Industry Development - Shanghe County has concentrated on extending, supplementing, and strengthening its industrial chains, successfully attracting and nurturing "chain master" enterprises while facilitating the integration of small and medium-sized enterprises into these chains [1] - The biopharmaceutical and chemical industry has seen significant growth, with 47 large-scale enterprises established, focusing on key pharmaceutical intermediates, high-end raw materials, and drug formulations, aiming for a target of 10 billion [1] - The equipment manufacturing sector has achieved multiple breakthroughs, with 42 large-scale enterprises including Guangri Co., Ltd. and the Jinan Digital Industry Park, leading to the development of industries such as laser manufacturing and elevator manufacturing [1] - The nutritional food industry is beginning to take shape, led by major enterprises like Sibote Bio and Jinsha River Noodle Industry, with the establishment of the Qilu Health Food Industrial Park and improvements in cold chain logistics [1]
ST未名: 《公司章程》(2025年7月)
Zheng Quan Zhi Xing· 2025-07-30 16:36
Core Points - The company is Shandong Sinobioway Biomedicine Co., Ltd., established in accordance with Chinese laws and regulations, with a registered capital of RMB 659,735,586 [2][6] - The company focuses on the biomedicine sector, aiming to address health issues through pharmaceutical research, manufacturing, and related services [4][5] - The company was approved for its initial public offering (IPO) in 2011, issuing 27.08 million shares [3] Company Structure - The company is a permanent corporation, with its legal representative being the board director or general manager [2][8] - The company has a total of 659,735,586 shares, all of which are ordinary shares [7][21] - The company is governed by its articles of association, which are legally binding for the company, shareholders, and management [3][12] Business Operations - The company's business scope includes biotechnology research, production and sales of pharmaceuticals, medical devices, and health management services [5][14] - The company aims to enhance its competitive edge in both domestic and international markets by integrating resources and improving innovation capabilities [4][14] Shareholder Rights and Responsibilities - Shareholders have rights to dividends, voting, and participation in company decisions, as well as obligations to comply with laws and the company's articles of association [13][40] - The company has provisions for shareholder meetings, including the requirement for a quorum and voting procedures [20][79] Governance and Compliance - The company is required to maintain transparency and comply with regulations regarding shareholder rights, including the disclosure of significant events [18][19] - The articles of association outline the responsibilities of controlling shareholders and actual controllers to protect the interests of the company and other shareholders [41][42]